Stifel Maintains Buy on EyePoint, Lowers Price Target to $5
Stifel analyst Annabel Samimy maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $6 to $5.
Last updated: 2026-11-19 06:07:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
EyePoint, Inc. (EYPT) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NASDAQ. The stock is currently priced at $0.28, with a market capitalization of $35.00M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.27 to $19.11. This page covers its latest market performance, valuation, price trends and company information.
$35.00M | |
$0.30 | |
$0.32 | |
$0.27 | |
$0.30 | |
2.86M | |
8.57M | |
-- | |
$19.11 | |
$0.27 | |
-- | |
2026-09-30 |
EyePoint, Inc. (EYPT) last closed at $0.28 as of 2026-11-19 00:59:00, down 6.96% ($0.02) from the previous close of $0.30.
During the latest regular trading session, EYPT traded between $0.27 and $0.32, with a volume of 2.86M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, EyePoint, Inc. (EYPT) moved from $0.36 to $0.28, representing a decline of 23.74% ($0.09).
The stock traded between $0.27 and $0.41 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 5.12 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.1%
EYPT is currently trading at $0.28, placing it 0.1% of the way from its 52-week low of $0.27 to its 52-week high of $19.11. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 214 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to EyePoint, Inc. and EYPT stock.
Stifel analyst Annabel Samimy maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $6 to $5.
Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares rose 13.88%
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
EyePoint (EYPT) reported a quarterly loss of $1.07 per share, missing the consensus estimate of $0.88, representing a -21.59% earnings surprise. The company's stock has declined 98.1% year-to-date versus the S&P 500's 11.3% gain. Despite beating revenue estimates, the company maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions. AnaptysBio (ANAB), a peer in the Medical - Biomedical and Genetics industry, is expected to report earnings of $0.41 per share with revenues down 58% year-over-year.
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.91) by 17.58 percent. This is a 25.88 percent decrease over losses of $(0.85) per
Eligible investors can buy real shares of EyePoint, Inc. (EYPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to EYPT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between EYPT shares and USD.
EYPT Shares to USD
1.00 EYPT shares = 0.276 USD
Calculations are estimates based on the latest available price and are for reference only.